FindTrial
Sign In

Analysis of the clinical application of oral administration of meglumine esophagography in the screening of esophageal fistula during the radiotherapy of esophageal cancer

Analysis of the clinical application of oral administration of meglumine esophagography in the screening of esophageal fistula during the radiotherapy of esophageal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015739
Enrollment
Unknown
Registered
2018-04-17
Start date
2018-05-01
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Gold Standard:Fiber esophagoscopy ?CT
Index test:Oral&#32
administration&#32
of&#32
meglumine&#32
diamamine&#32
esophagography&#32

Sponsors

Mianyang Central Hospita
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Preliminary diagnosis of esophageal carcinoma with radical intensity modulated radiation therapy

Exclusion criteria

Exclusion criteria: Iodized anaphylaxis, severe liver and kidney dysfunction, and combined active pulmonary tuberculosis, multiple myeloma, and hyperthyroidism

Design outcomes

Primary

MeasureTime frame
Esophageal fistula;—

Countries

China

Contacts

Public ContactWu Rong

Mianyang Central Hospital

shiyunjiuye@163.com+86 15882862062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026